Stockscreener 앱 받기
0.72
1.14%
-0.0083
시장 영업 전:
.73
0.01
+1.39%
Sangamo Therapeutics Inc 주식(SGMO)의 최신 뉴스
Sangamo Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
5 Best Stem Cell Companies to Invest In (May 2025) - Securities.io
Press Release Distribution & PR Platform - ACCESS Newswire
Fabry Disease Market: Epidemiology, Drugs, Companies, DelveInsight | Amicus Therapeutics, CHIESI Farmaceutici and Protalix Biotherapeutics, Sanofi (Genzyme), Takeda Pharmaceuticals, Sangamo Therapeuti - The Globe and Mail
Sangamo Therapeutics to Present Neurology Pipeline Advances at t - GuruFocus
Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) - Business Wire
Sangamo Therapeutics, Inc. (SGMO) Shareholders May Have Been Affected by FraudLevi & Korsinsky Investigates - ACCESS Newswire
Form 4Statement of changes in beneficial ownership of securities - ADVFN
Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System - Zenopa
Sangamo announces capsid license agreement with Eli Lilly - MSN
Lilly, Sangamo Enter Capsid License Agreement - Contract Pharma
Another rebound as Sangamo inks $1.4B capsid deal with Lilly - BioWorld MedTech
Lilly Licenses Sangamo’s Capsid Technology For CNS Gene Therapy - insights.citeline.com
Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal (SGMO) - Seeking Alpha
Sangamo Thera enters critical deal with Lilly - The Pharma Letter
Lilly Throws Sangamo a Lifeline With Pact Worth Potential $1.4B+ - BioSpace
Lilly throws lifeline to Sangamo with $1.4bn licensing deal - pharmaphorum
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga
Sangamo Therapeutics stock soars on Lilly licensing deal By Investing.com - Investing.com India
RH, FIVE, SGMO, BAC, TSLA: Top 5 Trending Stocks TodayFive Below (NASDAQ:FIVE), Bank of America (NYSE:BAC) - Benzinga
Sangamo Therapeutics (SGMO) Signs Major Licensing Deal with Eli Lilly - GuruFocus
Sangamo Therapeutics (SGMO) Surges on Licensing Deal with Eli Li - GuruFocus
Sangamo licenses brain-targeting capsid to Lilly in $1.4 billion deal By Investing.com - Investing.com South Africa
Sangamo licenses brain-targeting capsid to Lilly in $1.4 billion deal - Investing.com Canada
Struggling Sangamo's brain-penetrating drug delivery tech attracts Eli Lilly in potential $1.4 billion pact - The Business Journals
Sangamo Therapeutics Announces Capsid License Agreement With Lilly To Deliver Genomic Medicines For Diseases Of The Central Nervous System - MarketScreener
Sangamo Therapeutics Stock Surges After The Bell: What's Going On? - Benzinga
Sangamo Signs Capsid License Deal With Eli Lilly; Shares Rise After Hours - MarketScreener
Sangamo Therapeutics stock soars on Lilly licensing deal - Investing.com
Sangamo Therapeutics, Inc. (SGMO) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
10 Promising Biotech Stocks to Invest in (May 2025) - Securities.io
Hunter Syndrome Treatment Market Generated Opportunities, - openPR.com
Fabry Disease Market Growth Projections 2023-2032: DelveInsight Analysis | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics - Barchart
Fabry Disease Market Growth Projections 2023-2032: - openPR
Sangamo Therapeutics’ SWOT analysis: gene therapy stock faces cash crunch amid pipeline progress By Investing.com - Investing.com South Africa
Sangamo Therapeutics’ SWOT analysis: gene therapy stock faces cash crunch amid pipeline progress - Investing.com India
Truist Removes Price Target From Sangamo Therapeutics, Keeps Buy Rating; Price Target Had Been $5 - MarketScreener
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - Zenopa
8 Analysts Assess Sangamo Therapeutics: What You Need To Know - Benzinga
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2024 Earnings Call Transcript - Insider Monkey
US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being' - Benzinga
IHS Holding, HealthEquity And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo
Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges - GuruFocus.com
Earnings call transcript: Sangamo Therapeutics Q4 2024 reveals minor EPS miss By Investing.com - Investing.com South Africa
Sangamo: Q4 Earnings Snapshot - mySA
Earnings call transcript: Sangamo Therapeutics Q4 2024 reveals minor EPS miss - Investing.com
0.39%
3.66%
자본화:
|
볼륨(24시간):